Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: Randomised study

British Medical Journal

Volumn 317, Issue 7155, 1998, Pages 379-384

  Schöffski, Patrick ^a   Freund, Mathias ^b,d   Wunder, R ^a   Petersen, D ^b   Kohne C H ^d   Hecker, H ^c   Schubert, U ^a   Ganser, A ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Department of Medicine ^*

^c Biometrical Department

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; DIURETIC AGENT; GLUCOSE; INTRALIPID; OPIATE; POTASSIUM;

ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DYSPNEA; EDEMA; FEASIBILITY STUDY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LEUKEMIA; LIVER FUNCTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; SOLID TUMOR; TREATMENT FAILURE; UNIVERSITY HOSPITAL;

EID: 0032497111     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.317.7155.379     Document Type: Article

References (25)

1. Lyman CA, Walsh TJ. Systemically administered antilungal agents. A review of their pharmacology and therapeutic application. Drugs 1992;44:9-35.
2. Khoo SH, Bond J, Denning DW. Administering amphotericin B a practical approach. J Antimicrob Chemother 1994;33:203-13.
3. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Inter Dis 1988;158:1065-70.
4. Joly V, Farinotti R, Saint-Julien L, Cheron M, Carbon C, Yeni P. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (fungizone) associated with intralipid. Antimicrob Agents Chemother 1991;38:177-83.
5. Caillot D, Chavanet P, Casasnovas O, Solary E, Zanetta G, Buisson M, et al. Clinical evaluation of a new lipid-based delivery system for intravenous administration of Amphotericin B. Eur J Clin Microbiol Infect Dis 1992;11:722-5.
6. Caillot D, Casasnovas O, Solary E, Chavanet P, Bonnotte B, Reny G, et al. Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9.
7. Macedo MCMA, Dullev FL, Ostronoff M, Machado CM, Zambon E, Masumoto C, et al. Effectivenes of amphotericin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients, Clin Infec Dis 1994;19;366-7.
8. Thakur CP. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azai. Trans R Soc Trop Med Hrg 1994;88:698-9.
9. Anderson RP, Clark DA. Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother 1995;29:496-500.
10. Joly V, Geoflray C, Reynes J, Gonjard C, Méchali D, Maslo C, et al. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. J Antimicrobiol Chemother 1996;38:117-26.
11. Villani P, Regazzi MB, Maserati R, Viale P, Alberici F, Giacchino R. Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients. Arzncimittelforschung 1996;46:145-9.
12. Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, D'Athis M, et al. Trial of glucose versus tat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992;305:921-5.
13. Moreau P, Milpied N, Fayette N, Rameé JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30:535-11.
14. Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994;33;603-13.
15. Mever P, Adam D, Hiddemann W, Link H, Maschmeyer G, Helmerking M. Interventionstherapic von Infektionen and Fiebei unklater Genese bei neutropenischen Patienten mit malignen hämatologischen Grunderkrankungen - Studie II. Zeitschrift für antimikrobielle antineoplastische Chemotherapie 1992;10:1-27.
16. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infec Dis 1992;11:99-109.
17. Schöffski P, Lutmann A, Petersen D, Schumann G, Rapp-Bernbardt U, Freund M, Amphotericin B - neue Darreichungsform cines berwährten Antimykotikums. Arzneimitteltherapie 1994;12:115-7.
18. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte translusions. N Engl J Med 1981;304:1185-9.
19. Arning M, Heer-Sonderhoff AH, Wehmeier A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infec Dis 1995;11:11-3.
20. Lindholm M. The ability of critically ill patients to eliminate fat emulsions. J Drug Dev 1991;4(suppl 3):10-2.
21. Sundström G, Zauner CW, Arborelius M, Decrease in pulmonary diffusion capacity during lipid infusion in healthy men. J Appl Physiol 1973;34:816-20.
22. Greene HL, Hazett D, Demaree R. Relationship between innalipid-induced hyperlipidemia and pulmonary function. Am J Clin Nutr 1976;29:127-35.
23. Belin RP, Bivins BA, Jona JZ, Young VL. Fat overload with a 10 sovbcan oil solution. Arch Surg 1976;111:1391-9.
24. Wesson DE, Rich R, Zlotkin SH, Pencharz PB, Fat overload syndrome causing respiratory insufficiency. J Pediatr Surg 1984;19:777-8.
25. Heide PE, Hohenberger H, Tensiometrische und konduktometrische Stabilitäts- untersuchungen von Amphotericin B in Fettemulsionen. Österreichische Krankenhaus Pharmazie 1996;10:36-43.